Burning Rock Biotech Limited (BNR) Fair Value & Analysis
Healthcare · US · Market cap $74.2M
Burning Rock Biotech Limited
BNR · US
Fair value as of: Aug 13, 2026
From 1 valuation models · updated today
Fair value updated Aug 13, 2026, revised from $8.09 to $7.91 (−2.2%) since Jul 15, 2026. Share price −6.5% over the past month.
A solid business, but screening 15% overvalued on our models.
What matters now
- Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range ($4.96 to $9.93) leaves room in how you read the outcome.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range $2.32 – $374.50 · fair‑value band $4.96 – $9.93 · the $9.29 price screens above the $7.91 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Burning Rock Biotech Limited (BNR) currently trades at $9.29, while our model-based Fair Value estimate is $7.91, implying the stock looks roughly 14.8% overvalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Burning Rock Biotech Limited generated revenue of $514M at a net margin of -11.5%. Revenue declined 18.9% year over year. It earns a return on equity of -10.9%. The balance sheet holds a net cash position of $438M. Fundamentals as of Aug 13, 2026
Our scenario range runs from $4.96 (bear case) to $9.93 (bull case); at $9.29, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 78% below its 52-week high and 204% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -50% fair-value upside, at -15%, BNR screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when BNR reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 57 · Market factors (momentum, volatility) 27
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.
Full company description
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Burning Rock Biotech Limited reported revenue of $540M in FY2025 versus $508M in FY2021, a compound +1.5%/yr. Reported net income was −$55.3M in FY2025.
BNR screens 15% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 135 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $603.01 | $308.19 | -49% |
| Danaher Corporation DHR | $205.79 | $103.88 | -50% |
| WuXi AppTec Co 2359 | HK$198.90 | HK$157.39 | -21% |
| Lonza Group LONN | CHF 566.20 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $570.58 | $255.77 | -55% |
| Agilent Technologies, Inc A | $148.24 | $61.53 | -58% |
| Waters Corporation WAT | $416.15 | $121.96 | -71% |
| IQVIA Holdings IQV | $243.84 | $132.17 | -46% |
| Illumina, Inc ILMN | $192.91 | $95.51 | -50% |
| Mettler-Toledo International Inc MTD | $1,437 | $615.78 | -57% |
Compare Burning Rock Biotech Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Burning Rock Biotech Limited (BNR) overvalued or undervalued?
What is the fair value of BNR?
What is the quality score of BNR?
What is the revenue of Burning Rock Biotech Limited (BNR)?
What is the net profit margin of BNR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Burning Rock Biotech Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.